Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Zogenix begins dosing in Phase Ib Relday multi-dose clinical trial to treat schizophrenia By PBR Staff Writer
US-based pharmaceutical firm Zogenix has started dosing patients in its multi-dose Phase Ib clinical trial of Relday, a proprietary, long-acting, subcutaneously injected formulation of risperidone being investigated to treat schizophrenia.
Drug Research > Drug Discovery & Development > News
Mast Therapeutics to develop vepoloxamer to treat chronic heart failure By PBR Staff Writer
US-based biopharmaceutical firm Mast Therapeutics is planning to develop vepoloxamer (MST-188) to treat patients with chronic heart failure.
Drug Research > Drug Discovery & Development > News Lilly partners with China's Innovent for new oncology therapies By PBR Staff Writer
Eli Lilly and Company and China-based biopharmaceutical firm Innovent Biologics have collaborated to create possible new treatment options for cancer patients in China and around the world.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Lilly partners with China's Innovent for new oncology therapies
By PBR Staff Writer
Eli Lilly and Company and China-based biopharmaceutical firm Innovent Biologics have collaborated to create possible new treatment options for cancer patients in China and around the world.
Drug Research > Drug Discovery & Development > News
AbbVie enters into license deal with C2N Diagnostics for Alzheimer's disease therapy
By PBR Staff Writer
US-based AbbVie and C2N Diagnostics, a protein diagnostic and therapeutic discovery firm, have collaborated for the development and commercialization of a portfolio of anti-tau antibodies to treat Alzheimer's disease (AD) and other neurological disorders.
Drug Research > Drug Discovery & Development > News
Lilly, Hanmi to develop BTK inhibitor to treat autoimmune diseases
By PBR Staff Writer
Eli Lilly and Company has entered into an exclusive license and collaboration agreement with Hanmi Pharmaceutical to develop and commercialize the latter's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, to treat autoimmune and other diseases.
Drug Research > Drug Discovery & Development > News
Stability Issues Related to Soft Gelatin Capsule Development
Stability issues are a challenge and never ending concern for formulators. The reactivity of formulations depends on many factors but it is generally recognized that labile drugs in aqueous forms are sometimes the worst cases and in this regard, this should be a true statement for the development teams which work with SGC´s.
Drug Research > Drug Discovery & Development > Press Releases
Amgen reports positive results from OSLER-1 and OSLER-2 trials of Repatha
By PBR Staff Writer
Amgen has reported positive one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase II (OSLER-1) and Phase III (OSLER-2) open-label extension trials of Repatha (evolocumab).
Drug Research > Drug Discovery & Development > News
Sanofi and Regeneron report 18-month results of ODYSSEY long term trial of Praluent
By PBR Staff Writer
Sanofi and Regeneron Pharmaceuticals have reported positive 18-month results of a Phase III ODYSSEY long term trial of Praluent (alirocumab), an investigational therapy, in patients with hypercholesterolemia.
Drug Research > Drug Discovery & Development > News
Evotec, Second Genome to discover new treatment for microbiome-mediated diseases
By PBR Staff Writer
German drug discovery firm Evotec and US-based biotechnology company Second Genome have entered into a partnership for small molecule-based discovery and development activities to treat microbiome-mediated diseases.
Drug Research > Drug Discovery & Development > News
EMD Serono amends deal with Opexa for multiple sclerosis drug Tcelna
By PBR Staff Writer
Merck subsidiary EMD Serono has made changes to its agreement with Opexa Therapeutics to develop and commercialize its investigational compound Tcelna (imilecleucel-T) for the treatment of multiple sclerosis.
Drug Research > Drug Discovery & Development > News
Korean biotech firm G-treeBNT obtains funding to develop RGN-259/GBT-201 in US
By PBR Staff Writer
RegeneRx Biopharmaceuticals' joint venture partner and licensee G-treeBNT is set to receive $7.28m from the Korean Government and Venture Fund to expand development of its product candidate, RGN-259 (GBT-201), in the US.
Drug Research > Drug Discovery & Development > News
Sandoz receives FDA approval for Zarxio
Generic pharmaceutical company Sandoz’s Zarxio has received an US Food and Drug Administration (FDA) approval for all indications included in the reference product's label.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests